Evidence map›Paper›PMID 39197168›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2024

Circulating free heme induces cytokine storm and pulmonary hypertension through the MKK3/p38 axis.

Mathews Valuparampil Varghese, Joel James, Dinesh Bharti, Franz Rischard, Olga Rafikova, Ruslan Rafikov

Abstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mathews Valuparampil VargheseDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.ORCID 0000-0002-8552-7359
Joel JamesDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.
Dinesh BhartiDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.
Franz RischardDepartment of Medicine, The University of Arizona College of Medicine - Tucson, Tucson, Arizona, United States.
Olga RafikovaDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.
Ruslan RafikovDivision of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.ORCID 0000-0001-5950-4076

Funding

Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension.R01HL132918 · NHLBI · UNIVERSITY OF ARIZONA · PI RAFIKOV, RUSLAN · 2016 to 2025
$4.5M
Hemolysis and Free Heme Signaling in Pulmonary HypertensionR01HL151447 · NHLBI · UNIVERSITY OF ARIZONA · PI Ruslan Rafikov · 2020 to 2026
$4.3M
Mitochondrial Dysfunction in Pulmonary HypertensionR01HL160666 · NHLBI · UNIVERSITY OF ARIZONA · PI Olga Rafikova · 2022 to 2026
$3.3M
HMGBG1 and Gender Difference in Pulmonary Arterial HypertensionR01HL133085 · NHLBI · UNIVERSITY OF ARIZONA · PI RAFIKOVA, OLGA · 2016 to 2020
$1.9M
Aminopeptidase N Driven Signaling in the Development of Pulmonary HypertensionR00HL171869 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Joel James · 2025 to 2026
$498k
Aminopeptidase N Driven Signaling in the Development of Pulmonary HypertensionK99HL171869 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI JAMES, JOEL · 2024 to 2025
$205k
American Heart Association-American Stroke Association 969574HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL132918HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL133085HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL151447HHS | NIH | NHLBI | Division of Intramural Research (DIR) K99HL171869NHLBI NIH HHS K99 HL171869NHLBI NIH HHS R00 HL171869NHLBI NIH HHS R01 HL132918NHLBI NIH HHS R01 HL133085NHLBI NIH HHS R01 HL151447NHLBI NIH HHS R01 HL160666NHLBI NIH HHS R24 HL123767
6 · The paper itself

Abstract

Hemolysis is associated with pulmonary hypertension (PH), but the direct contribution of circulating free heme to the PH pathogenesis remains unclear. Here, we show that the elevated levels of circulating free heme are sufficient to induce PH and inflammatory response in mice and confirm the critical role of mitogen-activated protein kinase kinase-3 (MKK3)-mediated pathway in free heme signaling. Following the continuous infusion of heme for 2 wk, wild-type (WT) but not MKK3 knockout (KO) mice develop PH, as evidenced by a significantly elevated right ventricular (RV) systolic pressure, RV hypertrophy, and pulmonary vascular remodeling. The MKK3/p38 axis, markedly activated by heme infusion in WTs, results in upregulated proliferative/cytokine signaling targets Akt, ERK1/2, and STAT3, which were abrogated in MKK3 KO mice. Moreover, the MKK3 KOs were protected against heme-mediated endothelial barrier dysfunction by restoring the tight junction protein zonula occludens-1 expression and diminishing the inflammatory cell infiltration in the lungs. Plasma cytokine multiplex analysis revealed a severe cytokine storm already 24 h after initiation of heme infusion, with a significant increase of 19 cytokines, including IL-1b, IL-2, IL-6, IL-9, and TNF-a, in WT animals and complete attenuation of cytokine production in MKK3 KO mice. Together, these findings reveal a causative role of circulating free heme in PH through activating inflammatory and proliferative responses. The central role of MKK3 in orchestrating the heme-mediated pathogenic response supports MKK3 as an attractive therapeutic target for PH and other lung inflammatory diseases linked to hemolytic anemia.

Indexed as

CytokinesHemeHypertension, PulmonaryMAP Kinase Kinase 3Mice, KnockoutAnimalsHumansLungMaleMAP Kinase Signaling SystemMiceMice, Inbred C57BLMitogen-Activated Protein Kinase 14p38 Mitogen-Activated Protein KinasesSignal TransductionCytokinesHemeMap2k3 protein, mouseMAP Kinase Kinase 3Mitogen-Activated Protein Kinase 14p38 Mitogen-Activated Protein Kinasescytokine stormfree hemep38 kinasepulmonary hypertensionvascular remodeling

Identifiers

PMID39197168
PMCPMC11482467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.